Latest news
PMN310 Shows No ARIA Signals in Early Alzheimer’s Phase 1b Trial - The Clinical Trial VanguardThe Clinical Trial Vanguard · Thu, 30 Jul 2026 06:41:50 GMTProMIS Neurosciences reports no ARIA‑E and favorable 6‑month biomarker trends for PMN310; 12‑month topline due Q1 2027 - TradingViewTradingView · Tue, 28 Jul 2026 10:13:00 GMTPMN: Interim results show strong safety and biomarker improvements for PMN310 in Alzheimer's disease - TradingViewTradingView · Tue, 28 Jul 2026 07:00:00 GMT